Combined small-cell lung carcinoma with dual false-negative diagnosis on preoperative biopsy and intraoperative frozen section: a case report highlighting sampling bias pitfalls
This case report highlights the diagnostic pitfalls of sampling bias in combined small-cell lung carcinoma, where severe intratumoral heterogeneity led to dual false-negative results on both preoperative biopsy and intraoperative frozen section, ultimately necessitating comprehensive FFPE analysis for accurate diagnosis and treatment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Lung cancer is not a single disease but a collection of different conditions, each behaving in its own way. Some types grow slowly, while others spread with terrifying speed. Among the most aggressive is a form called small-cell lung cancer, a disease where cells multiply rapidly and often hide in the lungs before causing obvious symptoms. Sometimes, a tumor is not just one type of cancer but a mix, containing both the fast-growing small cells and a different, slower-growing type. This mixture makes the tumor a chameleon, changing its appearance in different spots. For doctors, this creates a difficult puzzle: if they take a tiny sample to look at under a microscope, they might only see the harmless-looking parts of the tumor, missing the dangerous cells entirely. When this happens, a patient might be told they have a benign condition, delaying the life-saving treatment they actually need.
In a recent report, researchers from Fuyang, China, describe a striking example of this diagnostic trap. They followed an eighty-year-old man who came to the hospital with a cough, chest tightness, and a low-grade fever. A scan of his chest revealed a solid lump in the lower part of his left lung, measuring 24 by 18 millimeters. The lump looked suspicious, and nearby lymph nodes were enlarged, suggesting the problem had already begun to spread. The medical team, suspecting cancer, first tried to confirm the diagnosis with a needle biopsy, a procedure where a thin needle is inserted through the skin to extract a small piece of tissue. The pathologists who examined this sample saw only chronic inflammation and scar tissue. They concluded the lump was not cancer, but a benign reaction to irritation.
The patient underwent surgery to remove the lump and check the surrounding lymph nodes. During the operation, the surgeons sent a piece of the tissue to a lab for an immediate analysis, known as a frozen section, which allows for a quick diagnosis while the patient is still on the operating table. The pathologists looked at this second sample and, once again, saw only inflammation and fibrosis. They reported that the tissue appeared benign. Based on these two negative results, the surgeons initially believed they were dealing with a non-cancerous condition. However, the team did not stop there. They removed the entire lump and the nearby lymph nodes to be examined more thoroughly after the surgery.
When the removed tissue was processed in the standard way, which involves preserving it in a special fluid and slicing it into very thin sections for detailed study, the true nature of the disease was revealed. The final examination showed that the lump was actually a rare and dangerous mix of two different cancers. About seventy percent of the tumor was made of small-cell lung cancer, the aggressive type that spreads quickly. The remaining thirty percent was squamous cell carcinoma, a different common form of lung cancer. The pathologists confirmed this by using special stains that highlighted the unique markers of each cell type. They also found that the cancer had spread to one of the lymph nodes near the center of the chest.
This case highlights a critical lesson for medical practice. The tumor was so mixed up that the tiny samples taken before and during surgery missed the cancerous parts entirely, capturing only the surrounding scar tissue and inflammation instead. This is known as sampling bias, where the piece of tissue examined does not represent the whole picture. Because the initial tests were wrong, the patient almost missed the window for the correct treatment. Once the true diagnosis was made, the medical team followed the standard guidelines for the aggressive small-cell component, prescribing a combination of chemotherapy and immunotherapy. This approach is necessary because even a small amount of the fast-growing cancer type dictates the treatment plan, regardless of how much of the slower-growing type is present.
The story of this patient serves as a reminder that medical imaging and quick tests are not always enough to rule out cancer, especially when a tumor is a complex mix of different cells. When a scan shows a suspicious lump but a quick tissue test says it is harmless, doctors must remain cautious. They cannot rely on a single small sample to make a final decision. Instead, they must wait for a complete examination of the entire removed tissue to ensure no dangerous cells are hidden in the mix. In this case, the thorough post-surgery analysis saved the patient from a misdiagnosis, allowing him to receive the specific treatment needed to fight a disease that had successfully disguised itself in the early stages.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.